LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, today announced that it has reached commercial terms with two leading pharmacy retail operators in Caracas, Venezuela, to support the planned deployment of its AI-powered prescription processing and pharmaceutical fulfillment platform. The initiative is expected to support the Company's broader Latin American commercialization strategy and establish an initial operational framework for its expanding AI-driven healthcare logistics ecosystem.
Venezuela is intended to serve as the initial target market for the planned pharmacy fulfillment initiative due to increasing interest in technology-enabled healthcare infrastructure solutions and opportunities for operational modernization within the country's pharmaceutical distribution sector. Management believes continued operational deployment and market evaluation within Venezuela may provide a framework for evaluating future expansion opportunities into additional South American markets as part of the Company's broader long-term regional commercialization strategy.
The Company's platform is designed to modernize and streamline traditional prescription fulfillment workflows through mobile-enabled prescription intake, artificial intelligence-based text recognition, automated inventory verification, fulfillment coordination, and delivery routing technologies. Management believes the platform addresses operational inefficiencies that currently exist throughout underserved healthcare distribution markets in Latin America.
Under the planned deployment initiative, the platform is intended to support participating pharmacy operators through improved prescription processing efficiency, reduced administrative overhead, optimized pharmacy inventory coordination, and enhanced customer accessibility through technology-enabled fulfillment and delivery systems. Management believes the initiative may provide several important commercial advantages, including initial entry into an active pharmaceutical retail environment within a major Latin American metropolitan market, commercial evaluation opportunities for the Company's healthcare logistics platform within a real-world operational setting, potential recurring transaction-based operational activity associated with prescription fulfillment volumes, and a scalable framework for future regional expansion opportunities throughout South America.
The Company stated that the planned pharmacy fulfillment initiative is intended to integrate with the ongoing development of its broader digital healthcare ecosystem, including telehealth applications, healthcare analytics infrastructure, patient engagement technologies, and AI-assisted healthcare coordination platforms currently under development. Management believes the integration of pharmacy fulfillment capabilities into the Company's expanding software and online infrastructure may enhance operational scalability, improve user accessibility, support future platform interoperability, and strengthen the Company's long-term digital healthcare commercialization strategy throughout Latin America.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "We believe pharmacy fulfillment represents a natural extension of our digital healthcare infrastructure strategy. By combining AI-enabled prescription processing, logistics coordination, and pharmacy retail participation, we are continuing development of healthcare technology solutions designed to support accessibility, operational efficiency, and scalability across Latin America."
The Company emphasized that the pharmacy fulfillment platform and related deployment activities remain subject to continued operational planning, technology integration, commercial readiness, applicable regulatory considerations, partner implementation timelines, financing availability, and market adoption. No assurance can be provided regarding the timing of any broader commercial deployment, transaction volumes, revenue generation, geographic expansion, or operational success of the platform or related technologies.
For more information, please visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
